FMC Corp Insider Sale: Exec HRO Scanlan Offloads 5,137 Shares Amid Flat Market Signals

Insider Selling at FMC: What It Means for Investors On September 28, 2026, Executive Vice President and Chief HRO Scanlan Jacqueline sold 5,137 shares of FMC at $9.58 per share, reducing her position to 63,558 shares. The trade occurred when the stock was trading near its 52‑week low of $9.07, a 22.6 % decline from the beginning of the year and a staggering 71.6 % drop over the past 12 months. The sale happened amid a relatively muted social‑media buzz (68 % intensity) and neutral sentiment, suggesting the move was not a headline‑making event for retail traders.

Insider Activity in Context Scanlan’s recent history shows a mix of buying and selling. She bought 42,232 shares in February 2026 at a price of zero—indicating a potentially internal allocation or vesting event—only to sell 1,404 shares the same day at $14.62. Earlier in September 2025, she sold two tranches totaling 8,967 shares at $33.64 and $34.00, a price roughly 35 % higher than the current trading level. In the broader company‑wide filing, the CEO and other senior executives have been both buying and selling in the past months, but the aggregate net position of insiders remains positive. The pattern suggests that while insiders are actively managing personal holdings, they are not engaging in large‑scale dumping that would signal a loss of confidence.

Implications for Investors The recent sale by Scanlan is small relative to her overall stake and to FMC’s total outstanding shares (market cap $1.15 B). It is unlikely to materially impact the stock price. However, the timing—coinciding with a deep year‑to‑date decline—could be interpreted as a routine rebalancing rather than a bearish signal. Investors should weigh the insider activity against the company’s strategic initiatives, notably the Brazilian regulatory filing for rimisoxafen and ongoing pipeline developments. These efforts could provide upside in the medium term if regulatory approvals materialize. The negative price‑earnings ratio of –0.43 reflects the company’s current loss position, a risk factor that must be considered alongside insider transactions.

Scanlan Jacqueline: A Transaction Profile Scanlan has traded approximately 23,000 shares in the past year, with a roughly even split between purchases and sales. Her buying activity tends to occur when share prices are high (e.g., September 2025), whereas her selling events often happen at lower valuations (e.g., February 2026 and September 2026). This pattern indicates a strategic, perhaps tax‑optimized, approach rather than speculative trading. As Chief HRO, her insider activity is consistent with a focus on internal equity allocation and personal wealth management, rather than a direct reflection of her view on FMC’s prospects.

Bottom Line for Financial Professionals While insider selling can sometimes portend a lack of confidence, Scanlan’s trade is modest and fits within her broader, balanced trading history. The broader insider activity at FMC remains predominantly bullish. Investors should monitor ongoing regulatory developments and FMC’s quarterly earnings for more substantive signals, rather than rely solely on the latest 4‑form sale.